551 related articles for article (PubMed ID: 16424063)
21. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Mills IW; Crossland A; Patel A; Ramonas H
Eur Urol; 2007 Aug; 52(2):503-9. PubMed ID: 17343981
[TBL] [Abstract][Full Text] [Related]
23. Tea beverage in chemoprevention of prostate cancer: a mini-review.
Saleem M; Adhami VM; Siddiqui IA; Mukhtar H
Nutr Cancer; 2003; 47(1):13-23. PubMed ID: 14769533
[TBL] [Abstract][Full Text] [Related]
24. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
25. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas.
Siddiqui IA; Zaman N; Aziz MH; Reagan-Shaw SR; Sarfaraz S; Adhami VM; Ahmad N; Raisuddin S; Mukhtar H
Carcinogenesis; 2006 Apr; 27(4):833-9. PubMed ID: 16387739
[TBL] [Abstract][Full Text] [Related]
27. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
30. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
31. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.
Scaltriti M; Belloni L; Caporali A; Davalli P; Remondini D; Rizzi F; Astancolle S; Corti A; Bettuzzi S
Carcinogenesis; 2006 May; 27(5):1047-53. PubMed ID: 16314398
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update.
Brausi M; Rizzi F; Bettuzzi S
Eur Urol; 2008 Aug; 54(2):472-3. PubMed ID: 18406041
[No Abstract] [Full Text] [Related]
33. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
[TBL] [Abstract][Full Text] [Related]
34. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
Marshall JR; Sakr W; Wood D; Berry D; Tangen C; Parker F; Thompson I; Lippman SM; Lieberman R; Alberts D; Jarrard D; Coltman C; Greenwald P; Minasian L; Crawford ED
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1479-84. PubMed ID: 16896036
[TBL] [Abstract][Full Text] [Related]
35. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
37. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of tea and its polyphenols against prostate cancer.
Siddiqui IA; Adhami VM; Saleem M; Mukhtar H
Mol Nutr Food Res; 2006 Feb; 50(2):130-43. PubMed ID: 16425281
[TBL] [Abstract][Full Text] [Related]
39. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
40. Green tea catechins for chemoprevention of prostate cancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis.
Perletti G; Magri V; Vral A; Stamatiou K; Trinchieri A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
